Joshua D Brown1, Pratik A Doshi2, Jeffery C Talbert2. 1. Institute for Pharmaceutical Outcomes & Policy, Department of Pharmacy Practice & Science, University of Kentucky College of Pharmacy, 789 S. Limestone St #292E, Lexington, KY, USA. Electronic address: josh.brown@uky.edu. 2. Institute for Pharmaceutical Outcomes & Policy, Department of Pharmacy Practice & Science, University of Kentucky College of Pharmacy, 789 S. Limestone St #292E, Lexington, KY, USA.
Abstract
BACKGROUND: Manufacturers provide free sample medications as a means to increase use of branded medications. Sample use varies year-to-year as branded product patents expire and new products come to market. OBJECTIVE: This study sought to describe the use of sample medications during 2009-2013 and assess individual characteristics associated with sample use. METHODS: Data from the 2009-2013 U.S. Medical Expenditure Panel Survey (MEPS) were used. MEPS asks participants whether they received each medication they are taking as a sample. The top 10 medications and medication classes used each year by volume were identified as well as the proportion of people who used at least one sample medication. The proportion of new initiators of medications were also classified as the percent who received a sample for the specific medication. Logistic regression was used to assess individual demographics, insurance, and medication characteristics associated with use. RESULTS: Prevalence of sample use ranged from 9.3% in 2009 to 6.2% in 2013. The most widely used sample medications included statins during 2009-2011, which changed to inhaled β-agonists in 2012-2013, as atorvastatin became available as a generic. The overall volume of the top 10 free sample medications decreased by one-third over this study period. In 2013, 12.6% of new insulin analog users and 11.0% of new oral contraceptive users receive these medications through samples. Regression analysis showed that U.S. Medicaid- and Medicare-insured persons were less likely to use samples compared to those with private insurance. CONCLUSIONS: Sample medication use has decreased as generic medications are becoming more used in the U.S. Copyright Â
BACKGROUND: Manufacturers provide free sample medications as a means to increase use of branded medications. Sample use varies year-to-year as branded product patents expire and new products come to market. OBJECTIVE: This study sought to describe the use of sample medications during 2009-2013 and assess individual characteristics associated with sample use. METHODS: Data from the 2009-2013 U.S. Medical Expenditure Panel Survey (MEPS) were used. MEPS asks participants whether they received each medication they are taking as a sample. The top 10 medications and medication classes used each year by volume were identified as well as the proportion of people who used at least one sample medication. The proportion of new initiators of medications were also classified as the percent who received a sample for the specific medication. Logistic regression was used to assess individual demographics, insurance, and medication characteristics associated with use. RESULTS: Prevalence of sample use ranged from 9.3% in 2009 to 6.2% in 2013. The most widely used sample medications included statins during 2009-2011, which changed to inhaled β-agonists in 2012-2013, as atorvastatin became available as a generic. The overall volume of the top 10 free sample medications decreased by one-third over this study period. In 2013, 12.6% of new insulin analog users and 11.0% of new oral contraceptive users receive these medications through samples. Regression analysis showed that U.S. Medicaid- and Medicare-insured persons were less likely to use samples compared to those with private insurance. CONCLUSIONS: Sample medication use has decreased as generic medications are becoming more used in the U.S. Copyright Â
Authors: Walid F Gellad; Haiden A Huskamp; Angela Li; Yuting Zhang; Dana Gelb Safran; Julie M Donohue Journal: J Gen Intern Med Date: 2011-07-13 Impact factor: 5.128
Authors: O Kenrik Duru; Susan L Ettner; Norman Turk; Carol M Mangione; Arleen F Brown; Jeffery Fu; Leslie Simien; Chien-Wen Tseng Journal: J Gen Intern Med Date: 2013-08-22 Impact factor: 5.128
Authors: R V Gibbons; F J Landry; D L Blouch; D L Jones; F K Williams; C R Lucey; K Kroenke Journal: J Gen Intern Med Date: 1998-03 Impact factor: 5.128
Authors: Sarah L Cutrona; Steffie Woolhandler; Karen E Lasser; David H Bor; Danny McCormick; David U Himmelstein Journal: Am J Public Health Date: 2008-01-02 Impact factor: 9.308
Authors: Gang Fang; Izabela E Annis; Joel F Farley; Nirosha Mahendraratnam; Ryan P Hickson; Til Stürmer; Jennifer G Robinson Journal: Pharmacotherapy Date: 2017-12-11 Impact factor: 4.705
Authors: Ryan P Hickson; Jennifer G Robinson; Izabela E Annis; Ley A Killeya-Jones; Gang Fang Journal: J Am Heart Assoc Date: 2019-04-02 Impact factor: 5.501
Authors: Ryan P Hickson; Jennifer G Robinson; Izabela E Annis; Ley A Killeya-Jones; Maarit Jaana Korhonen; Ashley L Cole; Gang Fang Journal: J Am Heart Assoc Date: 2017-10-19 Impact factor: 5.501